Misako Nagasaka, MD, discusses key findings from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.